SG11202107488PA - Methods of treating breast cancer with tucatinib - Google Patents

Methods of treating breast cancer with tucatinib

Info

Publication number
SG11202107488PA
SG11202107488PA SG11202107488PA SG11202107488PA SG11202107488PA SG 11202107488P A SG11202107488P A SG 11202107488PA SG 11202107488P A SG11202107488P A SG 11202107488PA SG 11202107488P A SG11202107488P A SG 11202107488PA SG 11202107488P A SG11202107488P A SG 11202107488PA
Authority
SG
Singapore
Prior art keywords
tucatinib
methods
breast cancer
treating breast
treating
Prior art date
Application number
SG11202107488PA
Other languages
English (en)
Inventor
Luke Walker
Christopher Endres
Anthony Lee
Hao Sun
Ariel Topletz-Erickson
Original Assignee
Seagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seagen Inc filed Critical Seagen Inc
Publication of SG11202107488PA publication Critical patent/SG11202107488PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202107488PA 2019-01-28 2020-01-24 Methods of treating breast cancer with tucatinib SG11202107488PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962797854P 2019-01-28 2019-01-28
PCT/US2020/014953 WO2020159822A1 (en) 2019-01-28 2020-01-24 Methods of treating breast cancer with tucatinib

Publications (1)

Publication Number Publication Date
SG11202107488PA true SG11202107488PA (en) 2021-08-30

Family

ID=69740562

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202107488PA SG11202107488PA (en) 2019-01-28 2020-01-24 Methods of treating breast cancer with tucatinib

Country Status (13)

Country Link
US (1) US20220193076A1 (zh)
EP (1) EP3917533A1 (zh)
JP (1) JP2022523045A (zh)
KR (1) KR20210119498A (zh)
CN (1) CN113613656A (zh)
AR (1) AR119681A1 (zh)
AU (1) AU2020215551A1 (zh)
CA (1) CA3126279A1 (zh)
IL (1) IL284850A (zh)
MX (1) MX2021008834A (zh)
SG (1) SG11202107488PA (zh)
TW (1) TW202042820A (zh)
WO (1) WO2020159822A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7328151B2 (ja) 2017-04-28 2023-08-16 シージェン インコーポレイテッド Ｈｅｒ２陽性がんの処置
WO2022067347A1 (en) * 2020-09-28 2022-03-31 Seagen Inc. Methods of treating solid tumors driven by her2 alterations with tucatinib in combination with an anti-her2 antibody
WO2024078628A1 (zh) * 2022-10-13 2024-04-18 山东大学 治疗骨质疏松的方法和药物组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
ATE154240T1 (de) 1992-03-12 1997-06-15 Alkermes Inc Acth enthaltende mikrokugeln mit gesteuerter abgabe
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
JP7328151B2 (ja) * 2017-04-28 2023-08-16 シージェン インコーポレイテッド Ｈｅｒ２陽性がんの処置

Also Published As

Publication number Publication date
US20220193076A1 (en) 2022-06-23
CA3126279A1 (en) 2020-08-06
KR20210119498A (ko) 2021-10-05
CN113613656A (zh) 2021-11-05
WO2020159822A1 (en) 2020-08-06
EP3917533A1 (en) 2021-12-08
IL284850A (en) 2021-08-31
TW202042820A (zh) 2020-12-01
AR119681A1 (es) 2022-01-05
MX2021008834A (es) 2021-09-28
JP2022523045A (ja) 2022-04-21
AU2020215551A1 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
IL275663A (en) Cancer treatment methods
IL269026A (en) Tumor treatment methods
IL267803A (en) Methods for treating cancer with anti-tim-3 antibodies
IL268394B2 (en) Adjuvant treatment for her2-positive breast cancer
IL284850A (en) Methods of treating breast cancer with toctinib
SG11202010793UA (en) Methods of treating cancer
IL284875A (en) Zofoxifene treatment for breast cancer
IL266324A (en) Treatment of her2-positive breast cancer
SG11202011117VA (en) Treatment of cancer
IL266917A (en) Methods for treating prolactin receptor-positive breast cancer
IL279591A (en) Cancer treatment methods using combination therapy
SG11202107017TA (en) Methods of treating cancer
IL289811A (en) A method for treating cancer
SG11202005163PA (en) Methods of treating cancer
IL281600A (en) Methods of treating cancer
IL277981A (en) Cancer treatment methods
IL290213A (en) Methods for treating multifocal cancer
IL269123A (en) Methods of treating cancer
IL269295A (en) Methods of treating breast cancer
EP3442555A4 (en) METHODS OF TREATING BREAST CANCER
EP3389670A4 (en) METHODS OF TREATING BREAST CANCER
IL265238A (en) Methods of prognosing breast cancer and treating same
SG11202103148QA (en) Methods of treating residual breast cancer with trastuzumab emtansine
GB201820975D0 (en) Methods of cancer treatment
GB201820098D0 (en) Methods of cancer treatment